Redenlab supporting new randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia

Redenlab are proud to support an upcoming randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia run by Professor David Coman & team from The University of Queensland.

Redenlab are providing resources for speech and swallowing testing across this 12 month trial.

Ataxia telangiectasia (A-T) is rare condition that affects the nervous system, the immune system, & many other parts of the body. Signs & symptoms of the condition usually begin in early childhood, often before age 5. The condition is typically characterized by cerebellar ataxia, oculomotor apraxia, telangiectasias, choreoathetosis (uncontrollable movements of the limbs), a weakened immune system with frequent infections, & an increased risk of cancers such as leukemia & lymphoma. A-T is caused by changes (mutations) in the ATM gene & is inherited in an autosomal recessive manner. Treatment is supportive & based on the signs & symptoms present in each person.

https://clinicaltrials.gov/ct2/show/NCT04513002

Related Post

  • Posted on 26 June, 2025
    Pain is deeply personal, yet universally expressed through speech. But what if speech isn’t just a way we describe pain,...
    • Posted on 17 June, 2025
      A new study published in the European Journal of Human Genetics provides the first systematic analysis of speech and language...
      • Posted on 15 May, 2025
        MEDIA RELEASE MELBOURNE, VIC – A major collaborative paper published in Alzheimer’s & Dementia introduces a critical roadmap for the...